Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

A. M. Parr, C. H. Tator, A. Keating

Research output: Contribution to journalReview articlepeer-review

423 Scopus citations


Transplantation of bone marrow-derived mesenchymal stromal cells (MSCs) into the injured brain or spinal cord may provide therapeutic benefit. Several models of central nervous system (CNS) injury have been examined, including that of ischemic stroke, traumatic brain injury and traumatic spinal cord injury in rodent, primate and, more recently, human trials. Although it has been suggested that differentiation of MSCs into cells of neural lineage may occur both in vitro and in vivo, this is unlikely to be a major factor in functional recovery after brain or spinal cord injury. Other mechanisms of recovery that may play a role include neuroprotection, creation of a favorable environment for regeneration, expression of growth factors or cytokines, vascular effects or remyelination. These mechanisms are not mutually exclusive, and it is likely that more than one contribute to functional recovery. In light of the uncertainty surrounding the fate and mechanism of action of MSCs transplanted into the CNS, further preclinical studies with appropriate animal models are urgently needed to better inform the design of new clinical trials.

Original languageEnglish (US)
Pages (from-to)609-619
Number of pages11
JournalBone marrow transplantation
Issue number7
StatePublished - Oct 2007

Bibliographical note

Funding Information:
A Keating holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation at University Health Network and the University of Toronto. A Parr is funded by the Canadian Institutes of Health Research and the University of Toronto.


Dive into the research topics of 'Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury'. Together they form a unique fingerprint.

Cite this